BIO-LOSARTAN TABLET
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
23-09-2015
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
LOSARTAN POTASSIUM
Available from:
BIOMED PHARMA
ATC code:
C09CA01
INN (International Name):
LOSARTAN
Dosage:
50MG
Pharmaceutical form:
TABLET
Composition:
LOSARTAN POTASSIUM 50MG
Administration route:
ORAL
Units in package:
100
Prescription type:
Prescription
Therapeutic area:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Product summary:
Active ingredient group (AIG) number: 0127971003; AHFS:
Authorization status:
CANCELLED POST MARKET
Authorization date:
2022-07-19
Summary of Product characteristics
_Bio-LOSARTAN _
_Page 1 of 36_
PRODUCT MONOGRAPH
PR BIO-LOSARTAN
Losartan Potassium Tablets
25, 50 and 100 mg
(House Standard)
Angiotensin II Receptor Antagonist
BIOMED PHARMA DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse September 14, 2015
Mont-Royal
Qc, H4T 1E2
Control # 186979
_Bio-LOSARTAN _
_Page 2 of 36_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
7
DRUG INTERACTIONS
................................................................................................................
9
DOSAGE AND ADMINISTRATION
..........................................................................................
11
OVERDOSAGE
............................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
13
STORAGE AND STABILITY
......................................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 16
PART II: SCIENTIFIC INFORMATION
.....................................................................................
17
PHARMACEUTICAL INFORMATION
......................................................................................
17
CLINICAL
Read the complete document
